Skip to main content
. Author manuscript; available in PMC: 2016 Nov 28.
Published in final edited form as: Cancer Discov. 2012 Aug 22;2(11):1036–1047. doi: 10.1158/2159-8290.CD-11-0348

Figure 4.

Figure 4

Combined PI3K and PARP suppression in vivo. Tumor growth of TNBC1, TNBC2, and TNBC3 xenografts treated with vehicle control, BKM120 (27.5 mg/kg), olaparib (Olap; 50 mg/kg), or the combination of both agents. Relative tumor volumes are displayed as mean ± SE of a minimum of 6 tumors per arm. *, P < 0.001 combination versus BKM120 arm.